Keflex Product Sales Total $3.1 Million in Quarter; Amoxicillin
PULSYS NDA Review Ongoing - PDUFA Date in January 2008 GERMANTOWN,
Md., Nov. 14 /PRNewswire-FirstCall/ -- MiddleBrook Pharmaceuticals,
Inc. (NASDAQ:MBRK), a pharmaceutical company focused on developing
and commercializing novel anti-infective products, today announced
financial and operational results for the quarter ended September
30, 2007. MiddleBrook reported third quarter 2007 revenue of $3.1
million, up from revenue of $2.7 million in the second quarter of
2007 and from $2.4 million in the third quarter of 2006. Revenue
for the first nine months of 2007 increased to $7.6 million, from
revenue of $3.6 million for the first nine months of 2006.
MiddleBrook reported research and development (R&D) expenses in
the third quarter of $5.5 million, compared to second quarter 2007
R&D expenses of $5.4 million and third quarter 2006 R&D
expenses of $5.7 million. Total expenses for the third quarter of
2007 were $13.2 million, compared to $12.2 million in the second
quarter of 2007 and $12.2 million in the third quarter of 2006. Net
loss was $10.1 million for the third quarter, compared to a net
loss of $9.5 million in the second quarter of 2007 and a net loss
of $9.9 million in the third quarter of 2006. Net loss for the
first nine months of 2007 was $33.2 million, compared to a net loss
of $28.2 million in the first nine months of the prior year. Net
loss per share applicable to common stockholders during the third
quarter of 2007 was ($0.22), compared to a net loss per share of
($0.21) in the prior quarter, and a net loss per share of ($0.33)
in the comparable quarter of last year. Net loss per share
applicable to common stockholders during the first nine months of
2007 was ($0.78), down from a net loss per share of ($0.93) in the
first nine months of 2006. "We believe the Amoxicillin PULSYS NDA
review process has progressed very well thus far and we look
forward to continuing to work with the FDA throughout the remainder
of their review," stated Edward M. Rudnic, Ph.D., president and CEO
of MiddleBrook. OPERATIONAL HIGHLIGHTS Amoxicillin PULSYS NDA
Review -- PDUFA Date January 23, 2008 On May 22, 2007,
MiddleBrook's New Drug Application (NDA) for its once- daily
Amoxicillin PULSYS product was accepted for filing by the U.S. Food
and Drug Administration (FDA). MiddleBrook has worked closely with
the FDA throughout the subsequent review process and anticipates a
decision on the application on its Prescription Drug User Fee Act
(PDUFA) target action date of January 23, 2008. Amoxicillin is
currently not approved for once-daily dosing to treat pharyngitis.
If approved for marketing, physicians prescribing Amoxicillin
PULSYS would have available the first once-daily product in the
aminopenicillin class for the treatment of pharyngitis while
utilizing approximately one-half the amount of amoxicillin
currently used. About 15 million patients annually seek relief of
sore throat symptoms in the United States. Keflex(R) Capsules
(Cephalexin, USP) -- Commercialization Update During the third
quarter, MiddleBrook continued the commercialization of its 750 mg
strength Keflex capsules through a targeted and dedicated national
contract sales force and MiddleBrook district sales managers. Based
on prescription data from IMS Health, total prescriptions filled
for Keflex 750 mg capsules in the third quarter of 2007 were 83,767
prescriptions, up from second quarter 2007 total prescriptions of
82,621. MiddleBrook recently conducted a review of its Keflex sales
initiatives and as a result reduced the size of its sales force to
approximately 30 contract sales representatives and three
MiddleBrook district sales managers. Financing Raises Up To an
Additional $10 Million in Gross Proceeds As announced on November
7, 2007, MiddleBrook closed an agreement with Deerfield Management,
a healthcare investment fund and one of the Company's largest
equity shareholders, raising up to $10 million in cash through the
sale of the Company's cephalexin assets, which the Company will
have the option to repurchase in the future. Under the terms of the
agreement, the Company received $7.5 million, less a $0.5 million
payment to Deerfield, with an additional $2.5 million to become
available, if necessary, if and when the Company receives FDA
approval of Amoxicillin PULSYS. The agreement is designed to
provide the Company with the financial flexibility to continue its
ongoing strategic discussions through the PDUFA date for
Amoxicillin PULSYS. The cash provided from the Deerfield agreement
also allowed MiddleBrook to repay in full its outstanding loan
facility with Merrill Lynch and eliminate the associated interest
and principal payments. Process to Explore Strategic Alternatives
Ongoing As previously announced, MiddleBrook's board of directors
authorized the Company to evaluate various strategic alternatives
to further enhance shareholder value. Subsequently, MiddleBrook
retained Pacific Growth Equities, LLC, an investment bank focused
on the life sciences industry, to assist in the evaluation of a
full range of strategic alternatives available to the Company.
Strategic alternatives the Company may pursue could include, but
are not limited to, continued execution of the Company's operating
plan, the sale of some or all of the Company's assets, partnering
or other collaboration agreements, or a merger or other strategic
transaction. There can be no assurance that the exploration of
strategic alternatives will result in any agreements or
transactions, or that, if completed, any agreements or transactions
will be successful or on attractive terms. The Company does not
intend to disclose developments with respect to this process unless
and until the evaluation of strategic alternatives has been
completed. FINANCIAL DETAILS -- Total revenue, resulting entirely
from net Keflex product sales, was $3.1 million in the third
quarter of 2007, up from revenue of $2.7 million in the prior
quarter, and $2.4 million for the third quarter of 2006. Revenue
for the quarter included $1.8 million that had been deferred in the
previous quarter, as well as one month's actual sales in the
quarter as the company resumed shipments of product in September
upon completion of relabeling. Revenue during the first nine months
of 2007 was $7.6 million, up from revenue of $3.6 million during
the first nine months of 2006. Increased product sales were mainly
attributable to the Company's Keflex 750 mg strength capsules which
were launched during the third quarter of 2006. -- Operating
expenses. Third quarter research and development expenses,
primarily consisting of salaries, stock-based compensation, and
related expenses for personnel and the costs of the Company's
clinical trials and research initiatives, were $5.5 million,
compared to $5.4 million in the previous quarter and $5.7 million
in the third quarter of 2006. Additional costs of $0.8 million were
incurred in the third quarter as the Company consolidated
operations into a single site, but these were offset by lower
personnel costs and reduced spending on developing the Company's
amoxicillin manufacturing facility. Selling, general and
administrative (SG&A) expenses totaled $6.5 million in the
third quarter of 2007, up from $6.3 million in the second quarter
of 2007, and $6.1 million in the third quarter of 2006. SG&A
expenses increased in the third quarter of 2007 versus the second
quarter of 2007 primarily due to costs associated with
consolidating operations into a single site. Stock-based
compensation recorded in the third quarter 2007 was a total of $0.7
million, consisting of $0.2 million recorded in R&D expense and
$0.5 million recorded in SG&A expense. In the second quarter
2007 and third quarter 2006, total stock-based compensation was an
expense of $0.7 million and $1.1 million, respectively. -- Net loss
for the third quarter of 2007 was $10.1 million. This compares to a
net loss of $9.5 million in the second quarter of 2007, and $9.9
million in the third quarter of 2006. Net loss for the first nine
months of 2007 was $33.2 million, compared to a net loss of $28.2
million for the first nine months of 2006. -- Net loss per share
applicable to common stockholders for the third quarter of 2007 was
($0.22), compared to a loss per common share of ($0.21) in the
prior quarter and ($0.33) in the third quarter of 2006. Per share
figures were computed on the basis of an average of 46.7 million
shares outstanding in the third quarter of 2007, 45.3 million
shares outstanding in the second quarter of 2007, and 30.3 million
shares outstanding in the third quarter of 2006. -- Cash and
marketable securities decreased by $6.3 million during the third
quarter. Changes were composed of $10.0 million of operating
losses, $0.7 million in loan payments; offset by $2.2 million for
non- cash expenses and $2.2 million for working capital changes and
other items. -- The Balance Sheet at the end of the third quarter
of 2007 reflected $5.9 million of unrestricted cash, cash
equivalents and marketable securities, compared to $12.2 million as
of June 30, 2007, and $12.6 million as of September 30, 2006.
Following the third quarter of 2007, MiddleBrook entered into an
agreement with Deerfield Management resulting in the addition of
$7.5 million of gross proceeds to the Company. MiddleBrook used a
portion of the proceeds from this financing to retire the Company's
outstanding credit facility of approximately $4.6 million. --
Deferred product revenue. Due to the Company's corporate name
change on June 28, 2007, inventories of products on hand at that
time were required to be relabeled. At the end of the second
quarter 2007, the Company offered a one-time incentive to
wholesalers to purchase up to a two-month supply of Keflex
products, to avoid stock-out situations at wholesalers during the
relabeling process. This incentive offer resulted in orders of
approximately $2.0 million of gross sales. Revenue recognition for
this transaction was deferred as of June 30, 2007, and the Company
recognized net revenue of $1.8 million during the third quarter of
2007, the period when the related product was sold by the
wholesalers. FINANCIAL GUIDANCE AND FUTURE CASH REQUIREMENTS As
previously announced, in order to preserve corporate resources, the
Company has undertaken cost reductions during 2007, including
personnel reductions, postponement of PULSYS clinical development
programs other than Amoxicillin PULSYS for adults, and elimination
of other discretionary spending. Total revenue for 2007 is expected
to be approximately $10 million to $12 million, resulting from
Keflex product sales. Total cash used in operating activities and
capital expenditures in 2007 is estimated to be between $33 and $35
million. Assuming the Company's expectations for continued sales of
its Keflex 750 mg product and anticipated level of R&D spending
and other obligations, MiddleBrook believes that its current funds,
together with expected Keflex product sales, will be sufficient to
support its currently planned operations through the Company's
PDUFA action date of January 23, 2008. These 2007 estimates are
forward-looking statements that involve risks and uncertainties,
and actual results could vary materially. CONFERENCE CALL The
Company has scheduled a conference call for today, Wednesday,
November 14, 2007 at 10:30 AM ET. During the call, Dr. Edward
Rudnic, president and CEO, and Robert Low, vice president, finance
and CFO, will discuss quarterly results and other corporate
activities. Investors can call 1-800-813-8504 (domestic) and
1-706-643-7752 (international) prior to the 10:30 AM start time and
ask for the MiddleBrook Pharmaceuticals conference call hosted by
Dr. Rudnic. A replay of the call will be available on November 14,
2007 beginning at 12:30 PM ET and will be accessible until
Wednesday, November 21, 2007 at 5:00 PM ET. The replay call-in
number is 1-800-642-1687 for domestic callers and 1-706-645-9291
for international callers. The access number is 23072308. The
conference call will also be broadcast simultaneously on the
Company's website, http://www.middlebrookpharma.com/. Investors
should click on the Investor Relations tab and are advised to go to
the website at least 15 minutes early to register, download, and
install any necessary audio software. The call will also be
archived on the MiddleBrook website. About Middlebrook
Pharmaceuticals: MiddleBrook Pharmaceuticals, Inc.
(NASDAQ:MBRKNASDAQ:formerlyNASDAQ:Advancis
PharmaceuticalNASDAQ:Corporation) is a pharmaceutical company
focused on the development and commercialization of anti-infective
drug products that fulfill substantial unmet medical needs in the
treatment of infectious disease. The Company is developing a
portfolio of anti-infective drugs based on its novel biological
finding that bacteria exposed to antibiotics in front-loaded
staccato bursts, or "pulses," are killed more efficiently and
effectively than those under standard treatment regimens. Based on
this finding, MiddleBrook has developed a proprietary, once-a-day
pulsatile delivery technology called PULSYS(TM). By examining the
resistance patterns of bacteria and applying its delivery
technologies, MiddleBrook has the potential to redefine infectious
disease therapy and significantly improve drug efficacy, shorten
length of therapy, and reduce drug resistance versus currently
available antibacterial products. For more on MiddleBrook, please
visit http://www.middlebrookpharma.com/. About Keflex: Keflex(R)
(cephalexin capsules, USP) is a first-generation cephalosporin
antibiotic shown to be active against strains of both gram-positive
and gram- negative aerobes in vitro and in clinical infections.
Keflex is indicated for treatment of the following infections:
respiratory tract infections, otitis media, skin and skin structure
infections, bone infections, and genitourinary tract infections.
More information on Keflex and prescribing information are
available at
http://www.middlebrookpharma.com/products_antibiotics/keflex_antibiotics.aspx.
This announcement contains historical financial information as of
and for three-month and nine-month periods ended September 30, 2007
and September 30, 2006 that is unaudited, and MiddleBrook assumes
no obligation to update this information based on new information
or future performance except as may be specifically required by
applicable law or regulation. The unaudited annual financial
information is subject to audit by independent accountants on an
annual basis following the close of each calendar year. This
announcement contains forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities and Exchange Act of 1934, as amended.
These statements are based on MiddleBrook's current expectations
and assumptions. These statements are not guarantees of future
performance and are subject to a number of risks and uncertainties
that would cause actual results to differ materially from those
anticipated. The words, "believe," "expect," "intend,"
"anticipate," and variations of such words, and similar expressions
identify forward-looking statements, but their absence does not
mean that the statement is not forward- looking. Statements in this
announcement that are forward-looking include, but are not limited
to, statements about the Company's product development and
commercialization schedule, including, particularly, future plans
with respect to its Amoxicillin PULSYS products; any statements
regarding Dr. Rudnic's comments and expectations concerning the
Company; the Company's initiatives to develop improved antibiotics;
the Company's existing and anticipated collaborative agreements;
and any financial forecasts and projections for 2007 and thereafter
included under the Financial Guidance section of this announcement.
The actual results realized by MiddleBrook could differ materially
from these forward-looking statements, depending in particular upon
the risks and uncertainties described in the Company's filings with
the Securities and Exchange Commission. These include, without
limitation, risks and uncertainties relating to the Company's
financial results and the ability of the Company to (1) raise
additional capital and continue as an ongoing concern, (2) increase
Keflex 750 sales, (3) obtain FDA approval for its Amoxicillin
PULSYS product candidate, (4) successfully reduce costs, (5)
maintain compliance with provisions under its financing
arrangements, (6) reach profitability, (7) prove that the
preliminary findings for its product candidates are valid, (8)
receive required regulatory approvals, (9) successfully conduct
clinical trials in a timely manner, (10) establish its competitive
position for its products, (11) develop and commercialize products
that are superior to existing or newly developed competitor
products, (12) develop products without any defects, (13) have
sufficient capital resources to fund its operations, (14) protect
its intellectual property rights and patents, (15) implement its
sales and marketing strategy, (16) successfully attract and retain
collaborative partners, (17) successfully commercialize and gain
market acceptance for its Keflex products, (18) successfully obtain
sufficient manufactured quantities of its drug products at
acceptable rates, and (19) retain its senior management and other
personnel. Existing and prospective investors are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of today's date. MiddleBrook undertakes no obligation
to update or revise the information in this announcement, whether
as a result of new information, future events or circumstances or
otherwise. MIDDLEBROOK PHARMACEUTICALS, INC. CONDENSED STATEMENTS
OF OPERATIONS (Unaudited) Three Months Ended Sept 30, Nine Months
Ended Sept 30, 2007 2006 2007 2006 Product sales $3,144,532
$2,369,975 $7,598,127 $3,566,563 Costs and expenses: Cost of
product sales 1,183,772 440,159 1,864,643 517,765 Research and
development 5,509,093 5,737,047 18,485,164 19,700,263 Selling,
general and administrative 6,475,742 6,069,529 20,473,947
13,001,312 Total expenses 13,168,607 12,246,735 40,823,754
33,219,340 Loss from operations (10,024,075) (9,876,760)
(33,225,627) (29,652,777) Interest income 126,655 221,333 481,855
747,921 Interest expense (159,359) (241,735) (528,924) (292,018)
Other income - - 75,000 976,815 Net loss $(10,056,779) $(9,897,162)
$(33,197,696) $(28,220,059) Basic and diluted net loss per share
$(0.22) $(0.33) $(0.78) $(0.93) Shares used in calculation of basic
and diluted net loss per share 46,650,833 30,302,628 42,831,867
30,209,948 MIDDLEBROOK PHARMACEUTICALS, INC. CONDENSED BALANCE
SHEETS (Unaudited) September 30, December 31, 2007 2006 ASSETS
Current assets: Cash and cash equivalents $4,987,690 $14,856,738
Marketable securities 929,812 522,723 Accounts receivable, net
1,331,764 303,514 Inventories, net 1,088,913 2,077,390 Prepaid
expenses and other current assets 1,199,515 1,682,685 Total current
assets 9,537,694 19,443,050 Property and equipment, net 11,533,248
11,764,627 Restricted cash 872,180 872,180 Deposits and other
assets 348,006 1,548,585 Intangible assets, net 7,509,070 8,377,327
Total assets $29,800,198 $42,005,769 LIABILITIES AND STOCKHOLDERS'
EQUITY Current liabilities: Accounts payable $2,991,269 $2,285,736
Accrued expenses and advances 5,898,096 7,817,224 Lines of credit
and short-term debt 4,888,889 6,888,889 Note payable - 75,000
Deferred product revenue - 189,000 Total current liabilities
13,778,254 17,255,849 Deferred contract revenue 11,625,000
11,625,000 Deferred rent and credit on lease concession 1,204,506
1,252,900 Total liabilities 26,607,760 30,133,749 Commitments and
contingencies Stockholders' equity: Preferred stock, undesignated -
- Common stock, par value 466,955 363,625 Capital in excess of par
value 189,008,385 164,593,930 Accumulated deficit (186,283,158)
(153,085,462) Accumulated other comprehensive income (loss) 256
(73) Total stockholders' equity 3,192,438 11,872,020 Total
liabilities and stockholders' equity $29,800,198 $42,005,769
MIDDLEBROOK PHARMACEUTICALS, INC. CONDENSED STATEMENTS OF CASH
FLOWS (Unaudited) Nine Months Ended September 30, 2007 2006 Cash
flows from operating activities: Net loss $(33,197,696)
$(28,220,059) Adjustments to reconcile net income to net cash used
in operating activities: Depreciation and amortization 3,447,503
2,949,486 Stock-based compensation 1,971,687 2,861,585 Deferred
rent and credit on lease concession (48,393) (4,297) Amortization
of premium on marketable securities (69,242) 222,332 Loss on
disposal of fixed assets 23,185 Recognition of advance payment for
potential sale of Keflex (1,000,000) Changes in: Accounts
receivable (1,028,251) (1,255,473) Inventories 988,477 (1,110,616)
Prepaid expenses and other current assets 483,170 220,484 Deposits
other than on property and equipment, and other assets 249,667 -
Accounts payable 705,533 1,215,109 Accrued expenses and advances
(1,975,496) 608,590 Deferred product and contract revenue (189,000)
270,061 Net cash used in operating activities (28,662,041)
(23,219,613) Cash flows from investing activities: Purchase of
marketable securities (5,867,519) (13,274,560) Sale and maturities
of marketable securities 5,530,000 19,655,000 Purchases of property
and equipment (246,330) (50,653) Deposits on property and equipment
(1,150,624) (250,000) Proceeds from sale of fixed assets - 25,000
Change in restricted cash - 730,444 Net cash provided by (used in)
investing activities (1,734,473) 6,835,231 Cash flows from
financing activities: Proceeds from issuance of debt, net of issue
costs - 7,792,976 Payments on lines of credit (2,000,000)
(1,913,062) Proceeds from private placement of common stock, net of
issue costs 22,412,260 - Proceeds from exercise of common stock
options 115,206 280,156 Net cash provided by financing activities
20,527,466 6,160,070 - - Net decrease in cash and cash equivalents
(9,869,048) (10,224,312) Cash and cash equivalents, beginning of
period 14,856,738 18,116,968 Cash and cash equivalents, end of
period 4,987,690 7,892,656 DATASOURCE: MiddleBrook Pharmaceuticals,
Inc. CONTACT: Robert Low, Vice President, Finance & CFO,
+1-301-944-6690, , or Bob Bannon, Vice President, Investor
Relations, +1-301-944-6710, , both of MiddleBrook Pharmaceuticals,
Inc. Web site: http://www.middlebrookpharma.com/
Copyright
Middlebrook Pharmaceuticals (MM) (NASDAQ:MBRK)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Middlebrook Pharmaceuticals (MM) (NASDAQ:MBRK)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024